175 related articles for article (PubMed ID: 38007537)
21. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
[TBL] [Abstract][Full Text] [Related]
22. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
23. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
[TBL] [Abstract][Full Text] [Related]
24. LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
Dey G; Bharti R; Braley C; Alluri R; Esakov E; Crean-Tate K; McCrae K; Joehlin-Price A; Rose PG; Lathia J; Gong Z; Reizes O
J Ovarian Res; 2023 Jun; 16(1):122. PubMed ID: 37370140
[TBL] [Abstract][Full Text] [Related]
25. A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
Trenner A; Godau J; Sartori AA
Mol Cancer Ther; 2018 Jul; 17(7):1392-1404. PubMed ID: 29654063
[TBL] [Abstract][Full Text] [Related]
26. Landscape analysis of lncRNAs shows that DDX11-AS1 promotes cell-cycle progression in liver cancer through the PARP1/p53 axis.
Xu M; Zhao X; Zhao S; Yang Z; Yuan W; Han H; Zhang B; Zhou L; Zheng S; Li MD
Cancer Lett; 2021 Nov; 520():282-294. PubMed ID: 34371129
[TBL] [Abstract][Full Text] [Related]
27. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
28. CRISPR/Cas9‑induced saturated mutagenesis identifies
Yang H; Wei Y; Zhang Q; Yang Y; Bi X; Yang L; Xiao N; Zang A; Ren L; Li X
Mol Med Rep; 2022 Aug; 26(2):. PubMed ID: 35713220
[TBL] [Abstract][Full Text] [Related]
29. Rad18 and Rnf8 facilitate homologous recombination by two distinct mechanisms, promoting Rad51 focus formation and suppressing the toxic effect of nonhomologous end joining.
Kobayashi S; Kasaishi Y; Nakada S; Takagi T; Era S; Motegi A; Chiu RK; Takeda S; Hirota K
Oncogene; 2015 Aug; 34(33):4403-11. PubMed ID: 25417706
[TBL] [Abstract][Full Text] [Related]
30. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
[TBL] [Abstract][Full Text] [Related]
31. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.
Verma P; Zhou Y; Cao Z; Deraska PV; Deb M; Arai E; Li W; Shao Y; Puentes L; Li Y; Patankar S; Mach RH; Faryabi RB; Shi J; Greenberg RA
Nat Cell Biol; 2021 Feb; 23(2):160-171. PubMed ID: 33462394
[TBL] [Abstract][Full Text] [Related]
32. E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway.
Yu Y; Zhao D; Li K; Cai Y; Xu P; Li R; Li J; Chen X; Chen P; Cui G
Cell Death Dis; 2020 Apr; 11(4):273. PubMed ID: 32332880
[TBL] [Abstract][Full Text] [Related]
33. RAD51-Mediated DNA Homologous Recombination Is Independent of
Sinha A; Saleh A; Endersby R; Yuan SH; Chokshi CR; Brown KR; Kuzio B; Kauppinen T; Singh SK; Baker SJ; McKinnon PJ; Katyal S
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138032
[TBL] [Abstract][Full Text] [Related]
34. RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma.
Pan M; Sha Y; Qiu J; Chen Y; Liu L; Luo M; Huang A; Xia J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175611
[TBL] [Abstract][Full Text] [Related]
35. RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks.
Dungrawala H; Bhat KP; Le Meur R; Chazin WJ; Ding X; Sharan SK; Wessel SR; Sathe AA; Zhao R; Cortez D
Mol Cell; 2017 Aug; 67(3):374-386.e5. PubMed ID: 28735897
[TBL] [Abstract][Full Text] [Related]
36. Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma.
Li Y; Zhuang W; Huang M; Li X
Biochem Biophys Res Commun; 2019 Jul; 514(4):1051-1057. PubMed ID: 31097223
[TBL] [Abstract][Full Text] [Related]
37. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
Pellegrino B; Herencia-Ropero A; Llop-Guevara A; Pedretti F; Moles-Fernández A; Viaplana C; Villacampa G; Guzmán M; Rodríguez O; Grueso J; Jiménez J; Arenas EJ; Degasperi A; Dias JML; Forment JV; O'Connor MJ; Déas O; Cairo S; Zhou Y; Musolino A; Caldas C; Nik-Zainal S; Clarke RB; Nuciforo P; Díez O; Serres-Créixams X; Peg V; Espinosa-Bravo M; Macarulla T; Oaknin A; Mateo J; Arribas J; Dienstmann R; Bellet M; Oliveira M; Saura C; Gutiérrez-Enríquez S; Balmaña J; Serra V
Cancer Res; 2022 Apr; 82(8):1646-1657. PubMed ID: 35425960
[TBL] [Abstract][Full Text] [Related]
38. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
39. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
40. Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51.
Zhao L; Si CS; Yu Y; Lu JW; Zhuang Y
Cancer Sci; 2019 Nov; 110(11):3543-3552. PubMed ID: 31541611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
